Incretin Mimetics Don't Raise Heart Failure Risk
Studies have raised concerns about the risk of heart failure with incretin mimetics, a class of type 2 oral and injected medications that includes exenatide (Byetta), linagliptin (Trajenta), liraglutide (Saxenda and Victoza), saxagliptin (Onglyza), and sitagliptin (Januvia). But those studies weren’t large enough to provide definitive proof. This time, researchers looked at records for nearly 1.5 million people in the United States, Canada, and the United Kingdom. The result: People with type 2 diabetes who had heart failure were no more likely to be taking incretins than any other type of diabetes drug.
Source: The New England Journal of Medicine, published online March 24, 2016